Improving Public Health in the Global South by Leveraging Innovative Smoke-free Alternatives, focus at Technovation’25
NEW DELHI, Oct. 14, 2025 /PRNewswire/ -- Philip Morris International (PMI) recently hosted…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu)…
Sanofi Hosts Regional Webinar on Protecting High-Risk Groups from Seasonal Influenza
Sanofi recently hosted a hybrid symposium titled "Safeguarding High-Risk Groups: The Importance…
Government Push for Generic Drugs Finds Digital Ally in New Healthcare Portal
India's healthcare landscape is undergoing a significant transformation, led by national initiatives…
First Key Update of the International AI Safety Report released
MONTREAL, Oct. 15, 2025 /PRNewswire/ -- The first Key Update of the…
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality
SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization…